Liver-Damaging Effects of Cholesterol Drug Zetia Hidden by Merck, FDA Documents Reveal

Email this article to a friend

Printable Version

Articles Related to This Article: • Trial Results for the Cholesterol Blocker Zetia Have Not Been Revealed • Expert Panel Recommends Doctors Abandon Vytorin Cholesterol Drug • Merck Delayed Release of Clinical Study Revealing Failure of Vytorin Cholesterol Drug Sign the Health Revolution Petition Join the call for genuine health freedom in America. End FDA tyranny and Big Pharma corruption. Watch the video and sign the petition here.

(NaturalNews) Documents on the FDA Web site reveal that pharmaceutical companies Merck and Schering-Plough conducted numerous safety studies on the popular cholesterol drug Zetia but did not publish the results, which suggested that the drug may cause liver damage when mixed with statins.

Zetia is a trade name for the drug ezetimibe, also marketed under the names Ezetrol and Ezemibe. It is a major seller for Merck and Schering, and is estimated to have earned them $5 billion in 2007.

The drug functions by blocking cholesterol absorption in the gut, and is often prescribed in conjunction with another class of cholesterol drugs, called statins. Because statins function in a different fashion by increasing the rate at which LDL cholesterol is cleared from the blood, the combination leads to a greater overall decrease in cholesterol levels. This combination is so popular that Merck and Schering also sell a combination Zetia-Zocor (simvastatin) pill under the brand names Vytorin and Inegy.

But concerns have long existed that the combination of Zetia and statins may lead to liver damage. As early as 2002, an FDA reviewer recommended against allowing the drugs to be mixed, due to liver damage in animal studies. Since the drug's approval, various case studies of liver damage have been published in medical journals.

The trials used to secure Zetia's FDA approval were all short-term studies, in which a total of 3,900 patients had been given Zetia for a maximum of 12 weeks. The time period covered by these studies is generally accepted to be too short for signs of liver damage to emerge in most patients. Yet even in these studies, the rate of health problems was 11 times higher among patients who took Zetia in combination with a statin than among those who took only statins. Nearly all serious health effects were liver-related.

Yet the FDA ruled that these risks were minor, and approved the drug without any request for longer term studies.

Now, careful examination of documents on the FDA web site reveals that the agency also saw the results of longer-term trials that showed more significant liver-related risks. But these studies were never published, leaving doctors and health researchers at large unaware of their results.

The exact results of the studies remain unknown. But allusions to them on the FDA Web site reveal that they were conducted between 2000 and 2003 and looked at several thousand patients who had been given a Zetia-statin combination for a period between one and two years. The statins tested include Lipitor, Crestor and Zocor, and there were signs of liver damage among patients who mixed these drugs with Zetia.

According to Robert J. Spiegel, chief medical officer at the Schering-Plough Research Institute, the results of the studies were not considered scientifically important enough for publication. But many health professionals have disputed this view.

"There is important evidence, but it's not in public view," said Dr. Harlan Krumholz, a Yale cardiologist. "It's hidden from investigators."

The concealment of the studies may also have been a violation of FDA rules that require results of all drug trials completed after October 2002 to be listed on industry Web sites.

Free registration is required to read the rest of this article...
Enter your email address to continue:  
Your email privacy is 100% protected by NaturalNews. We do not sell, rent or share emails.


Get articles like this delivered to you FREE in our popular email newsletter

Related CounterThink Cartoons:

Related Articles: • Trial Results for the Cholesterol Blocker Zetia Have Not Been Revealed • Expert Panel Recommends Doctors Abandon Vytorin Cholesterol Drug • Merck Delayed Release of Clinical Study Revealing Failure of Vytorin Cholesterol Drug	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/024072_Zetia_Merck_cholesterol_drug.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.NaturalNews.com/024072_Zetia_Merck_cholesterol_drug.html">Liver-Damaging Effects of Cholesterol Drug Zetia Hidden by Merck, FDA Documents Reveal</a>